ArticleJournal of clinical immunology2019
Novel Gain-of-Function Mutation in Stat1 Sumoylation Site Leads to CMC/CID Phenotype Responsive to Ruxolitinib.
Tariq Al Shehri et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
16 papers cite it
this paperpooled itcites it